Cbd Life Science Stock Price, News & Analysis

CBD Life Sciences (OTC:CBDL) reports that President Trump's administration is actively considering rescheduling marijuana from Schedule I to Schedule III under the Controlled Substances Act. This potential regulatory shift could transform the $30+ billion cannabis market by eliminating IRS Section 280E restrictions and opening doors for institutional investment.

The rescheduling would enable cannabis companies to deduct ordinary business expenses, improve net margins, and facilitate access to banking services. With nearly 70% of Americans supporting legalization, CBDL is positioning itself through retail expansion, including recent approval for sales on Walmart Marketplace, to capitalize on the anticipated industry growth following regulatory reform.

CBD Life Sciences (OTC:CBDL) announced its participation in the NECANN Cannabis Conference, scheduled for September 5-6, 2025, in Atlantic City, NJ. The company will showcase its flagship brand The CBD Vault at Booth 837.

NECANN New Jersey, ranked as the 3rd largest B2B cannabis convention in the US, is expected to attract over 5,000 attendees and feature more than 200 exhibitors. The event provides CBDL with opportunities to strengthen distribution networks, expand market reach, and connect with potential investors in the Mid-Atlantic region.

The global CBD market is projected to reach $69 billion by 2029, with a CAGR exceeding 31%. This exhibition aligns with CBDL's strategy to enhance brand visibility and capture market share in one of the nation's fastest-growing regions.

CBD Life Sciences Inc. (OTC:CBDL) has announced its expansion into Las Vegas, entering final negotiations for a premium retail location near the Las Vegas Strip. The company is also in advanced discussions with a Nevada-based boutique wellness retailer to carry CBDL's products.

The Las Vegas CBD market showed 27% year-over-year growth in 2024 and is projected to exceed $550 million by 2026. The strategic location will provide access to over 30 million annual visitors and leverage the city's 150,000+ hotel rooms for maximum brand exposure.

The expansion includes plans to offer CBDL's product line including CBD bath bombs, skincare items, and 8000mg pain relief creams through high-touchpoint boutique channels.

CBD Life Sciences (OTC:CBDL) is finalizing a lease agreement for its second retail location in Arizona's Chandler Fashion Center, marking a significant expansion of its physical presence. The strategic move positions CBDL in a high-traffic mall environment operated by a major management company overseeing 20+ retail properties nationwide.

The new store will showcase CBDL's premium product lines, including their 8000mg Nano CBD Pain Cream, Delta-8 Gummies, Mushroom Gummies, and CBD Coffee Creamers. The location will offer in-store sampling, education, and wellness consultations.

This expansion aligns with projections for the U.S. CBD market to reach $36 billion by 2032, growing at a 21.7% CAGR. The strategic location in a premier mall positions CBDL to capture significant foot traffic and potentially expand to other locations through the mall operator's nationwide network.

CBD Life Sciences (OTC:CBDL) has announced a strategic partnership with the Vibe Performance Network to market its flagship 8000MG Pain Relief Cream through major streaming platforms including Hulu, ESPN+, Roku, and Discovery+.

The company will leverage Vibe's data-driven advertising platform to target health-conscious consumers with precision demographics and geographic targeting. This strategic move is expected to generate a projected 7-figure boost in annual revenue. The initiative comes as the global CBD market is forecasted to reach $22 billion by 2030, with topical CBD products expected to achieve a 32.1% CAGR.

CBD Life Sciences Inc. (CBDL) reported an extraordinary 1,502.30% revenue increase from January through May 2025, reflecting an annualized growth rate over 4,000%. The company has successfully transformed from a CBD-focused business to a diversified wellness brand, expanding across multiple retail channels including Walmart Marketplace, DoorDash, Leafly, and Groupon. CBDL's growth is driven by product innovation in functional wellness, including mushroom smoothies, brain support blends, and adaptogenic supplements. The company has established presence in both digital and physical platforms, with popular products like 3000MG Pain Relief Cream and male vitality supplements. Under CEO Lisa Nelson's leadership, CBDL is capitalizing on the expanding CBD and mushroom supplement markets, projected to reach $30 billion and $15 billion respectively by 2028.

CBD Life Sciences Inc. (CBDL) has launched an innovative line of CBD-infused vaginal and rectal suppositories, entering the $2.8 billion suppository market. The product aims to provide targeted relief for conditions including menstrual cramps, endometriosis, pelvic floor dysfunction, and gastrointestinal discomfort. The suppositories offer superior bioavailability compared to oral CBD products by delivering CBD directly into the bloodstream through the pelvic region or lower bowel. The global pharmaceutical suppositories market, valued at $1.6 billion in 2022, is projected to grow at a 5.7% CAGR to reach $2.8 billion by 2032, with North America holding the largest market share. Local healthcare professionals in Scottsdale, Arizona, have shown interest in the therapeutic potential of these suppositories, validating the product's market readiness.

CBD Life Sciences (CBDL) has announced the launch of a new 500MG Delta-8 THC gummy product, expanding its cannabinoid wellness portfolio. The lab-tested gummies, available in Blue Razz & Strawberry flavors, are manufactured in-house and will be sold through www.thecbdvault.com. The product launch aligns with growing Delta-8 market projections, expected to reach $2.1 billion by 2026.

The gummies are designed to offer various wellness benefits, including pain relief, anxiety and stress support, nausea control, appetite stimulation, and potential neuroprotective effects. Unlike Delta-9 THC, Delta-8 provides a milder psychoactive experience. Each batch undergoes independent lab testing to ensure purity, potency, and compliance.

CBD Life Sciences Inc. (CBDL) has announced a strategic manufacturing partnership with Jeannie in a Bottle, an Arizona-based CBD company. Under this agreement, CBDL will handle the production, packaging, and labeling of high-potency CBD products exclusively for Jeannie in a Bottle, which has a presence in over 100 gas stations and convenience stores across the United States.

The partnership leverages Jeannie in a Bottle's established retail network while utilizing CBDL's manufacturing capabilities. This collaboration is expected to generate consistent monthly reorders and strengthen CBDL's revenue pipeline through ongoing production contracts. The deal strategically positions CBDL to expand its national presence in the growing CBD wellness market through the convenience store and gas station retail channel.